Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents

This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considera...

Full description

Saved in:
Bibliographic Details
Main Author: Hirakawa, Akihiro (Author)
Format: Electronic eBook
Language:English
Published: Tokyo : Springer Japan , 2018.
Edition:1st ed. 2018.
Series:JSS Research Series in Statistics,
Subjects:
ISBN:9784431555735
ISSN:2364-0057
Online Access: Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000nam a22000005i 4500
003 SK-BrCVT
005 20220618101452.0
007 cr nn 008mamaa
008 180130s2018 ja | s |||| 0|eng d
020 |a 9784431555735 
024 7 |a 10.1007/978-4-431-55573-5  |2 doi 
035 |a CVTIDW11749 
040 |a Springer-Nature  |b eng  |c CVTISR  |e AACR2 
041 |a eng 
100 1 |a Hirakawa, Akihiro.  |4 aut 
245 1 0 |a Modern Dose-Finding Designs for Cancer Phase I Trials: Drug Combinations and Molecularly Targeted Agents  |h [electronic resource] /  |c by Akihiro Hirakawa, Hiroyuki Sato, Takashi Daimon, Shigeyuki Matsui. 
250 |a 1st ed. 2018. 
260 1 |a Tokyo :  |b Springer Japan ,  |c 2018. 
300 |a XIII, 89 p. 3 illus.  |b online resource. 
490 1 |a JSS Research Series in Statistics,  |x 2364-0057 
500 |a Mathematics and Statistics  
505 0 |a 1. Introduction -- 2. Phase I Trials for Drug Development in Oncology -- 3. A Summary of Dose -- Finding Methods in Standard Phase I Trials -- 4. Phase I Trials for Combination of Two Agents -- 5. Phase I Trials for Joint Assessment of Both Efficacy and Toxicity -- 6. Additional Topics on Adaptive Dose -- Finding Methods. 
516 |a text file PDF 
520 |a This book deals with advanced methods for adaptive phase I dose-finding clinical trials for combination of two agents and molecularly targeted agents (MTAs) in oncology. It provides not only methodological aspects of the dose-finding methods, but also software implementations and practical considerations in applying these complex methods to real cancer clinical trials. Thus, the book aims to furnish researchers in biostatistics and statistical science with a good summary of recent developments of adaptive dose-finding methods as well as providing practitioners in biostatistics and clinical investigators with advanced materials for designing, conducting, monitoring, and analyzing adaptive dose-finding trials. The topics in the book are mainly related to cancer clinical trials, but many of those topics are potentially applicable or can be extended to trials for other diseases. The focus is mainly on model-based dose-finding methods for two kinds of phase I trials. One is clinical trials with combinations of two agents. Development of dose-finding methods for two-agent combination trials requires reasonable models that can adequately capture joint toxicity probabilities for two agents, taking into consideration possible interactions of the two agents on toxicity probability such as synergistic or antagonistic effects. Another is clinical trials for evaluating both efficacy and toxicity outcomes in single- and two-agent combination trials. These methods are often applied to the phase I trials including MTAs because the toxicity and efficacy for a MTA does not monotonically increase with dose, but the efficacy often increases initially with the dose and then plateaus. Successful software implementations for several dose-finding methods are introduced in the book, and their operating characteristics in practice are discussed. Recent advance of the adaptive dose-finding methods in drug developments are also provided. 
650 0 |a Statistics . 
650 0 |a Biostatistics. 
856 4 0 |u http://hanproxy.cvtisr.sk/han/cvti-ebook-springer-eisbn-978-4-431-55573-5  |y Vzdialený prístup pre registrovaných používateľov 
910 |b ZE09029 
919 |a 978-4-431-55573-5 
974 |a andrea.lebedova  |f Elektronické zdroje 
992 |a SUD 
999 |c 237527  |d 237527